Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative medications function by mimicking the natural actions of GLP-1, a hormone released by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds enhance insulin secretion and reduce glucag

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing variations in their pharmacolog